Live
- MVA united, will decide on CM post in Maha within a day
- Top pharma companies to invest Rs 5,260 cr, create 12,490 jobs in TG
- MIR Group to invest Rs 1500 cr in Mangalore SEZ
- Shivamogga farmers in panic after areca nut’s likely carcinogenic risk
- Union Minister tenders apology for remarks on Justice D’Cunha
- Indian value systems withstood many onslaughts: TG Guv
- Golden Chariot luxury train to resume operations from Dec 14
- Jain monk Shri 108 Jnaneshwar Muni attains samadhi at Devlapur
- Home minister flags off sports tournament of journalists
- Collector reviews development, welfare programmes in Kalasapadu mandal
Dr Reddy’s YoY Q1 net profit vaults 671per cent at Rs 456 crore
Dr Reddys Laboratories on Thursday posted 671 per cent yearonyear rise in net profit at Rs 45610 crore for the quarter ended June The pharmaceutical major had posted a net profit of Rs 5910 crore in the corresponding quarter last year
Hyderabad: Dr Reddy’s Laboratories on Thursday posted 671 per cent year-on-year rise in net profit at Rs 456.10 crore for the quarter ended June. The pharmaceutical major had posted a net profit of Rs 59.10 crore in the corresponding quarter last year.
The company’s revenues registered a 12 per cent and 5 per cent jump YoY and QoQ respectively with the gross margins ending up on the higher side with 55.7 per cent jump.
While the R&D expenses stood at Rs 416 crore (11.2 per cent of revenues), the profit before tax stood at Rs 501 crore, which is 13.5 per cent of the revenues.
Revenue from emerging markets, global generics, pharmaceutical services and APIs stood at Rs 660 crore (up 16 percent YoY), Rs 3,060 crore (up 12 percent YoY) and Rs 540 crore (up 16 percent YoY), respectively. Revenues from India grew by 30 per cent (YoY) at Rs 610 crore.
Speaking to the media, Dr Reddy's co-chairman and CEO GV Prasad said, “The rise in the net profit is mainly due to the launch of ‘gSuboxone’ (which is indicated for treatment of opioid dependence) in the US market, forex gains and operational efficiencies.”
However, Prasad admitted that the Suboxone verdict will have negative impact on the ongoing performance, at least for the next 3-4 quarters. “We are cautiously optimistic. While there is pricing pressure in the US market, there is also opportunity elsewhere and US."
On job cuts, Prasad said, “We let go 150-200 positions in the mid-management level as they have become redundant. It is an ongoing process. Big phase of cuts is over.”
As of June 30, cumulatively 112 generic filings are pending for approval with the USFDA {including three New Drug Applications (NDA).} Of the109 NDAs pending with the FDA, 61 are Para IVs out of which the company believes 30 have 'First to File status.’
